Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRING study of tipranavir/ritonavir with standard of care versus therapeutic drug monitoring in treatment-experienced HIV infection
2005-005264-86Phase 3Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tipranavir and ritonavir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Treatment response at Week 48. Started Jan 2007; status: terminated.
02
Drugs
tipranavirritonavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2005-005264-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005264-86.